
Kite set to acquire Tmunity Therapeutics
pharmafile | December 21, 2022 | News story | Medical Communications |
Santa Monica, US-based Kite is set to acquire Philadelphia, US-based Tmunity Therapeutics: a clinical stage, private biotech company. The financial details of the deal have not been announced, however it is expected to be finalised during the first quarter of 2023.
It is expected that Tmunity’s current employees will join Kite after the deal closes. This deal provides Kite not only with new employees, but also access to Tmunity’s pre-clinical and clinical programmes, which include an ‘armoured’ CAR T cell technology platform, and rapid manufacturing processes.
Tmunity will keep its prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA) assets separate from the deal. However, Kite will take over the ongoing R&D collaboration between Tmunity and Penn, known as the Amended Research License Agreement (ARLA), which will be extended until 2026 upon the closing of the deal, with the opportunity for further extensions.
The founders of Tmunity are set to become senior scientific advisors for Kite once the deal closes next year.
Christi Shaw, Kite’s chief executive officer, commented: “We believe that the impact cell therapy is making today is just the start of what is possible. […] Together, we bring a deep understanding of cell therapy as an effective platform, and combined with Kite’s industry-leading global scale, we collectively have a singular focus, to use cell therapy to develop potential cures, and to get them to patients as quickly as possible.”
Betsy Goodfellow






